These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
778 related articles for article (PubMed ID: 25813447)
21. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma. Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE Oncology; 2014; 87(6):342-50. PubMed ID: 25227656 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study. Lebacle C; Bensalah K; Bernhard JC; Albiges L; Laguerre B; Gross-Goupil M; Baumert H; Lang H; Tricard T; Duclos B; Arnoux A; Piedvache C; Patard JJ; Escudier B BJU Int; 2019 May; 123(5):804-810. PubMed ID: 30288884 [TBL] [Abstract][Full Text] [Related]
23. PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy. Hakimi K; Campbell SC; Nguyen MV; Rathi N; Wang L; Meagher MF; Rini BI; Ornstein M; McKay RR; Derweesh IH BJU Int; 2024 Apr; 133(4):425-431. PubMed ID: 37916303 [TBL] [Abstract][Full Text] [Related]
24. External Validation of Contact Surface Area as a Predictor of Postoperative Renal Function in Patients Undergoing Partial Nephrectomy. Haifler M; Ristau BT; Higgins AM; Smaldone MC; Kutikov A; Zisman A; Uzzo RG J Urol; 2018 Mar; 199(3):649-654. PubMed ID: 28941921 [TBL] [Abstract][Full Text] [Related]
25. Does the Renal Parenchyma Adjacent to the Tumor Contribute to Kidney Function? A Critical Analysis of Glomerular Viability in Partial Nephrectomy Specimens. Khemees TA; Lam ET; Joehlin-Price AS; Mortazavi A; Phillips GS; Shabsigh A; Sharp DS; Zynger DL Urology; 2016 Jan; 87():114-9. PubMed ID: 26505834 [TBL] [Abstract][Full Text] [Related]
26. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131 [TBL] [Abstract][Full Text] [Related]
27. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer]. Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823 [TBL] [Abstract][Full Text] [Related]
28. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. Bonate PL; Suttle AB Cancer Chemother Pharmacol; 2013 Jul; 72(1):231-40. PubMed ID: 23715625 [TBL] [Abstract][Full Text] [Related]
29. [Partial nephrectomy on solitary kidney: Renal function outcome and predictive factors of impairment]. Pierquet G; Zongo D; Robert G; Pasticier G; Maurice-Tison S; Bensadoun H; Ballanger P; Rouget B; Ferriere JM; Bernhard JC Prog Urol; 2016 Jan; 26(1):34-40. PubMed ID: 26654468 [TBL] [Abstract][Full Text] [Related]
30. Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma. Iizuka J; Kondo T; Hashimoto Y; Kobayashi H; Ikezawa E; Takagi T; Omae K; Tanabe K Int J Urol; 2012 Nov; 19(11):980-6. PubMed ID: 22735049 [TBL] [Abstract][Full Text] [Related]
31. R.E.N.A.L. Score Outperforms PADUA Score, C-Index and DAP Score for Outcome Prediction of Nephron Sparing Surgery in a Selected Cohort. Borgmann H; Reiss AK; Kurosch M; Filmann N; Frees S; Mager R; Tsaur I; Haferkamp A J Urol; 2016 Sep; 196(3):664-71. PubMed ID: 27091569 [TBL] [Abstract][Full Text] [Related]
33. Parenchymal volume preservation and ischemia during partial nephrectomy: functional and volumetric analysis. Mir MC; Campbell RA; Sharma N; Remer EM; Simmons MN; Li J; Demirjian S; Kaouk J; Campbell SC Urology; 2013 Aug; 82(2):263-8. PubMed ID: 23791213 [TBL] [Abstract][Full Text] [Related]
34. Partial nephrectomy without hilar control or cooling: longitudinal data over 5 years. Corcoran AT; Hayn MH; Gibbons EP; Mori R; Hrebinko R; Davies BJ Can J Urol; 2009 Oct; 16(5):4820-5. PubMed ID: 19796457 [TBL] [Abstract][Full Text] [Related]
35. Uric acid levels correlate with baseline renal function and high levels are a potent risk factor for postoperative chronic kidney disease in patients with renal cell carcinoma. Jeon HG; Choo SH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM J Urol; 2013 Apr; 189(4):1249-54. PubMed ID: 23159461 [TBL] [Abstract][Full Text] [Related]